[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 16, 1990

Surgery

JAMA. 1990;263(19):2684-2685. doi:10.1001/jama.1990.03440190140076
Abstract

Carcinoma of the breast afflicts in excess of 110 000 women in the United States annually. Dramatic improvements in cosmetic results from breast reconstruction have been demonstrated, particularly in the restoration of contour, symmetry, and the areola-nipple complex. A number of centers with extensive reconstructive experience and follow-up of their patients have recommended that immediate reconstruction be routinely offered to women with operable breast cancer because of the positive psychosocial benefits experienced by these patients.1

The second alert from the National Cancer Institute was issued in 1989 that involved the efficacy and results of adjuvant levamisole and fluorouracil therapy for patients who had Duke's group C colon cancer. In this study, the 5-year recurrence rate in the nontreated group (n = 135) vs the treated group (n = 136) was 55% and 41%, respectively; the median survival to recurrence was 14 months in the nontreated group and 23 months in the

×